AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05098847
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab plus lenvatinib will be initiated on day 14 after cryoablation. Sintilimab will be administered at 200 mg i.v. every 3 weeks.
Trial: NCT05098847
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sintilimab plus lenvatinib will be initiated on day 14 after cryoablation. Lenvatinib (bodyweight ≥ 60 kg, 12 mg; \< 60 kg, 8 mg) was given orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
Trial: NCT06747975
Drug: Dexamethasone and Ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients will receive Caudal epidural block (0.5 mL/kg of bupivacaine 0.25% plus dexa- methasone 0.1 mg/kg plus 4mg ondansetron ), and IV 5 mL normal saline
Trial: NCT06747975
Drug: Bupivacaine + saline
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients will receive caudal epidural block (0.5 mL/kg of bupivacaine 0.25% only) and IV 5 mL normal saline
Trial: NCT06752044
Drug: PD-1 inhibitor
RxNorm normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with PD-1 inhibitors will begin after the completion of radiotherapy, with a treatment cycle of 3 weeks. On the first day (D1) of each treatment cycle, the drug is administered intravenously, with the dosage according to the instructions.
Trial: NCT06752343
Drug: Clobetasol
RxNorm normalized name: Clobetasol
DrugBank: Clobetasol (DB11750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The OLP on the other side was treated by daily sticking a cut-to-size carrier with 0.025 CLO for 8 days~Other Names:~topical steroid administration
Trial: NCT06755684
Drug: Befotertinib combined Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Befotertinib combined Bevacizumab
Trial: NCT06755684
Drug: Befotertinib combined platinum-based double chemotherapy
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Befotertinib combined platinum-based double chemotherapy
Trial: NCT06752408
Drug: Osimertinib
RxNorm normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Osimertinib will be administered orally at a dose of 80 mg per time, Q.D.
Trial: NCT06147648
Drug: Tacrolimus Sustained-release Capsules
RxNorm normalized name: tacrolimus Extended Release Oral Tablet
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transition from Immediate-release tacrolimus to prolonged-release tacrolimus at 3 months after liver transplantation
Trial: NCT06749756
Drug: vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On the basis of the basic treatment of sepsis, intravenous vitamin C 50mg/kg q6h was given for 4 days.
Trial: NCT06749756
Drug: 0.9%Nacl
RxNorm normalized name: triamcinolone acet/0.9%NaCl/PF 40 mg/mL INJECTION VIAL (ML)
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The same dose of placebo (0.9% sodium chloride solution) was administered on top of the sepsis base treatment for 4 days.
Trial: NCT06754865
Drug: Antibiotic
RxNorm normalized name: Antibiotics
DrugBank: Gramicidin D (DB00027)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic
Trial: NCT06745193
Drug: chidamide+Camrelizumab+Apatinib
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chidamide+Camrelizumab+Apatinib
Trial: NCT06745193
Drug: Irinotecan or Docetaxel or Paclitaxel
RxNorm normalized name: Medicated Pad or Tape
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan Docetaxel Paclitaxel
Trial: NCT06753565
Drug: Carnitine
RxNorm normalized name: carnitine
DrugBank: Levocarnitine (DB00583)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: It is a nutritional supplement with trade name  Carnitol® in Egypt.
Trial: NCT06756061
Drug: Prednisone + Jakavi(ruxolitinib)
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The experimental group will receive ruxolitinib 10 mg orally twice daily (BID) and prednisone (or equivalent) at a dosage of 1 mg/kg/day.~Subjects are orally administered with an investigational medicinal product (IMP) according to their designated treatment group for 48 weeks, and the investigator may adjust the dosage of IMPs based on symptoms of the target disease. (However, after the 48-week mark, participants in the ruxolitinib treatment group may continue to receive ruxolitinib for an additional maximum of 2 years, based on the investigator's judgment regarding the need for ongoing treatment. The total duration of ruxolitinib administration will not exceed 3 years.)
Trial: NCT06756061
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The control group will receive prednisone (or equivalent) at a dosage of 1 mg/kg/day.~Subjects are orally administered with an investigational medicinal product (IMP) according to their designated treatment group for 48 weeks, and the investigator may adjust the dosage of IMPs based on symptoms of the target disease.
Trial: NCT06755528
Drug: Chitosan
RxNorm normalized name: Chitosan
DrugBank: Chitosan low molecular weight (20-200 mpa.s) (DB14155)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participants will receive medications for fallopian tube adhesions (Chitosan (glucosamine (GIcN) and N-acetylglucosamine (GIcNAc) units,1 tablet per day) as prescribed by the gynecologist
Trial: NCT05393076
Drug: Linerixibat
RxNorm normalized name: LINERIXIBAT
DrugBank: Linerixibat (DB11729)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linerixibat dose and administration as per study intervention.
Trial: NCT06753721
Drug: Doxorubicin liposome combined with CapOX and Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab (7.5 mg/kg, IV, Day 1) + Oxaliplatin (130 mg/m², IV, Day 1) + Capecitabine (1000 mg/m², oral, twice daily, for 14 days) + Doxorubicin liposome (20 mg/m², IV, Day 1), repeated every 3 weeks.
Trial: NCT06753890
Drug: Changkang granules
RxNorm normalized name: monofluorophosphate
DrugBank: Monofluorophosphate ion (DB02348)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5g/bag, 1 bag per dose, 2 doses per day, oral，4 consecutive weeks.
Trial: NCT06756308
Drug: Enasidenib
RxNorm normalized name: Enasidenib
DrugBank: Enasidenib (DB13874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enasidenib 100 mg daily on 28-day cycles.
Trial: NCT06756308
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV rituximab 375 mg/m² weekly for the first month, and monthly thereafter
Trial: NCT06751992
Drug: Conversion to extended-release tacrolimus
RxNorm normalized name: tacrolimus Extended Release Oral Tablet
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conversion from immediate-release tacrolimus (Prograf) to extended-release tacrolimus (Envarsus XR) as a part of the maintenance immunosuppressive treatment
Trial: NCT06751992
Drug: Maintenance of immediate-release tacrolimus
RxNorm normalized name: tacrolimus Extended Release Oral Tablet
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuing immediate-release tacrolimus (Prograf) as a part of the maintenance immunosuppressive treatment
Trial: NCT06755346
Drug: Cannabis plant (THC 20mg)
RxNorm normalized name: Cannabis indica top
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabis flower - very High THC (\>10%) / Low CBD (\<1%)
Trial: NCT06755346
Drug: Cannabis (0%/ THC / 0% CBD)
RxNorm normalized name: Cannabis indica top
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC (0%) / CBD (0%) - Placebo marijuana
Trial: NCT06755346
Drug: Cannabis plant (THC 40mg)
RxNorm normalized name: Cannabis indica top
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabis flower - very High THC (\>10%) / Low CBD (\<1%)
Trial: NCT04936711
Drug: Marcaine
RxNorm normalized name: Marcaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Marcaine spray at incision site after closure
Trial: NCT06738043
Drug: Dexmedetomidine infusion
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A bolus dose of dexmedetomidine (0.5 µg/kg ideal body weight) diluted in 0.9% normal saline is infused over 10 minutes before induction of anesthesia, followed by a continuous infusion at 0.5 µg/kg/h until 10 minutes before the end of surgery.
Trial: NCT06738043
Drug: Ketamine infusion
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A bolus dose of ketamine (0.3 mg/kg ideal body weight) diluted in 0.9% normal saline is infused over 10 minutes before induction of anesthesia, followed by a continuous infusion at 0.3 mg/kg/h until 10 minutes before the end of surgery.
Trial: NCT06738043
Drug: Normal Saline Infusion (Placebo)
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A bolus dose of 0.9% normal saline is infused over 10 minutes before induction of anesthesia, followed by a continuous infusion of 0.9% normal saline until 10 minutes before the end of surgery.
Trial: NCT06738017
Drug: BMN 349
RxNorm normalized name: DNA (synthetic adeno-associated virus 5 vector BMN 270 human blood-coagulation factor VIII SQ variant-specifying)
DrugBank: Tipapkinogene sovacivec (DB06239)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250mg oral tablet
Trial: NCT06766474
Drug: Bupivacain
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: to our knowledge, this study is the 1st to compare the efficacy of bupivacaine hydrochloride-soaked dressing versus subcutaneous infiltration for postoperative donor site pain control for patients undergoing STSG procedures.
Trial: NCT06764186
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 2 intramuscular injections of 500 mg given on Day 1 of Weeks 1 and 3 of cycle 1, and then on Day 1, Week 1 of each cycle thereafter.
Trial: NCT06764186
Drug: Capivasertib
RxNorm normalized name: Capivasertib
DrugBank: Capivasertib (DB12218)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg (2 oral tablets) BD given on an intermittent weekly dosing schedule. Dosed on Days 1 to 4 in each week of a 28-day treatment cycle
Trial: NCT05748587
Drug: Deferoxamine
RxNorm normalized name: Deferoxamine
DrugBank: Deferoxamine (DB00746)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intramuscular deferoxamine (200 mg/kg) injection to rats
Trial: NCT05632926
Drug: 40 mg CBL-514
RxNorm normalized name: OH-Cbl
DrugBank: Hydroxocobalamin (DB00200)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CBL-514 will be administered at the raised area of cellulite.
Trial: NCT05632926
Drug: 60 mg CBL-514
RxNorm normalized name: OH-Cbl
DrugBank: Hydroxocobalamin (DB00200)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CBL-514 will be administered at the raised area of cellulite.
Trial: NCT05632926
Drug: 80 mg CBL-514
RxNorm normalized name: OH-Cbl
DrugBank: Hydroxocobalamin (DB00200)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CBL-514 will be administered at the raised area of cellulite.
Trial: NCT06247410
Drug: Rotigotine 8Mg/24Hrs Patch
RxNorm normalized name: ROTIGOTINE 8MG/24HRS PATCH
DrugBank: Rotigotine (DB05271)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once daily patch application of one Rotigotine 8Mg/24Hrs Patch (Test or Reference) over 4 days
Trial: NCT05338931
Drug: AT101(Anti-CD19 Chimeric Antigen Receptor T cell)
RxNorm normalized name: CAR.CD19-Redirected T cells
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-CD19 Chimeric Antigen Receptor T cell
Trial: NCT05069350
Drug: bupivacaine 0.5% and oxubuprocaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: using each drug as surface anesthesia before intravitreal injections
Trial: NCT04642365
Drug: RO7296682
RxNorm normalized name: RO7296682
DrugBank: RO7296682 (DB17531)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO7296682 will be administered as per the schedules specified in the respective arms.
Trial: NCT04642365
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab will be administered as per the schedules specified in the respective arms.
Trial: NCT05727098
Drug: Bupivacaine Hydrochloride
RxNorm normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: injection of Bupivacaine 0.25% in ESPB
Trial: NCT05727098
Drug: Bupivacaine Hydrochloride and dexmedetomedine
RxNorm normalized name: bupivacaine and meloxicam
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: injection of Bupivacaine 0.25% and dexmedetomedine in ESPB
Trial: NCT05727098
Drug: Bupivacaine Hydrochloride and ketamine
RxNorm normalized name: Ketamine Hydrochloride
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: injection of Bupivacaine 0.25% and ketamine in ESPB
Trial: NCT05643872
Drug: PTX-022
RxNorm normalized name: PTX-100
DrugBank: PTX-100 (DB18125)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QTORIN rapamycin 3.9% anhydrous gel
Trial: NCT00255554
Drug: Escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06387134
Drug: Lifei Xiaoji Wan
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Lifei Xiaoji Wan consists of ginseng, blackhead,rhubarb, aster, forehu, and thin on.
Trial: NCT06081673
Drug: Penpulimab injection
RxNorm normalized name: Penpulimab
DrugBank: Penpulimab (DB16747)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penpulimab is a human immunoglobulin G1(IgG1) monoclonal antibody (mAb) directly programmed cell death-1 (PD-1). AK105 can effectively prevent human PD-1 binds to programmed cell death-1 ligand 1(PD-L1) and programmed cell death-1 ligand 2(PD-L2)； 200mg,D1, IV(21 days/cycle).
Trial: NCT06081673
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin :75mg/m2, D1, IV(21 days/cycle)
Trial: NCT06081673
Drug: albumin-paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: albumin-paclitaxel :260mg/m2,IVgtt,D1(21 days/cycle)
Trial: NCT06760533
Drug: Psilocybin 25 mg
RxNorm normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psilocybin 25 mg (active treatment) administered during the psychotherapy treatment session.
Trial: NCT06760533
Drug: Niacin 100 mg
RxNorm normalized name: niacin 100 MG
DrugBank: Niacin (DB00627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niacin 100 mg (placebo) administered during the psychotherapy treatment session.
Trial: NCT06771154
Drug: Adebelimab Combined with Apatinib
RxNorm normalized name: aminophenazone, combinations with psycholeptics
DrugBank: Aminophenazone (DB01424)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy Phase (Total of 6 cycles, each cycle 21 days) Carboplatin AUC 5 mg/mL/min, administered on the first day of each cycle. Paclitaxel 175 mg/m², intravenous infusion for 3 hours, administered on the first day of each cycle.~Adebelizumab, Fixed dose of 1200 mg per administration, on the first day of each cycle, until the end of chemotherapy or until treatment is discontinued due to disease progression, intolerable toxicity, or other reasons specified in the protocol.~Maintenance Therapy Phase (Each cycle 21 days) Adebelimab, Fixed dose of 1200 mg per administration, IV (intravenous), Q3W (every 3 weeks), on the first day of each cycle, for a maximum of two years; Apatinib, 250 mg, once daily (qd), orally (po). Treatment continues until disease progression, intolerable toxicity, or other reasons specified in the protocol result in discontinuation.
Trial: NCT06771154
Drug: Adebelimab
RxNorm normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy Phase (Total of 6 cycles, each cycle 21 days) Carboplatin AUC 5 mg/mL/min, administered on the first day of each cycle. Paclitaxel 175 mg/m², intravenous infusion for 3 hours, administered on the first day of each cycle.~Adebelizumab, Fixed dose of 1200 mg per administration, on the first day of each cycle, until the end of chemotherapy or until treatment is discontinued due to disease progression, intolerable toxicity, or other reasons specified in the protocol.~Maintenance Therapy Phase (Each cycle 21 days) Adebelimab, Fixed dose of 1200 mg per administration, IV (intravenous), Q3W (every 3 weeks), on the first day of each cycle, for a maximum of two years; Treatment continues until disease progression, intolerable toxicity, or other reasons specified in the protocol result in discontinuation.
Trial: NCT06764251
Drug: Tislelizumab + SOX
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tislelizumab combined with SOX
Trial: NCT06771518
Drug: Atezolizumab 1200 mg e.v. q21
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Radiotherapy treatment associated with Atezolizumab 1200 mg i.v. q21 administered according to clinical practice
Trial: NCT06687980
Drug: Dupilumab
RxNorm normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pharmaceutical form: Solution for injection Route of administration: subcutaneous injection
Trial: NCT05019950
Drug: NIM-1324
RxNorm normalized name: L-pyroglutamyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-Nim-benzyl-histidyl-L-leucyl-L-arginyl-L-proline ethylamide
DrugBank: Histrelin (DB06788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once daily oral tablet
Trial: NCT06265259
Drug: Initiation of vasopressine as a first vasoconstrictive drug
RxNorm normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The group (arm 1) where vasopressin (1 amp in 50 mlN/S) (1st vasoconstrictor) will be administered first up to a maximum dose of 0.03 IU/min (2.3 ml/h) for the treatment of hemodynamic instability. Then, if the patient remains unstable, noradrenaline (2nd vasoconstrictor) will be started. The dose of vasopressin will not be increased further than the above mentioned limit.
Trial: NCT06265259
Drug: Initiation of noradrenaline as a first vasoconstrictive drug
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ii. In the group (arm 2) where the treatment of haemodynamic instability will be performed by first administering noradrenaline (1st vasoconstrictor) up to 0,5 mcg/kg/min and then, if the patient is still unstable, adding vasopressin (2nd vasoconstrictor) at a maximum dose of 0.03 IU/min (2.3ml/h). If haemodynamic instability persists, treatment will involve further increase of the noradrenaline dose.
Trial: NCT05897320
Drug: Eptinezumab
RxNorm normalized name: Eptinezumab
DrugBank: Eptinezumab (DB14040)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Solution for infusion
Trial: NCT06004882
Drug: Triamcinolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given by Injection
Trial: NCT06004882
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given by Injection
Trial: NCT04740918
Drug: Trastuzumab Emtansine
RxNorm normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab emtansine 3.6 mg/kg IV infusion
Trial: NCT04740918
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab 1200 mg IV infusion
Trial: NCT05201066
Drug: decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Solution for intravenous infusion
Trial: NCT05201066
Drug: spartalizumab
RxNorm normalized name: Spartalizumab
DrugBank: Spartalizumab (DB14892)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for intravenous infusion
Trial: NCT05201066
Drug: sabatolimab
RxNorm normalized name: Sabatolimab
DrugBank: Sabatolimab (DB16322)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for intravenous infusion
Trial: NCT05201066
Drug: azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Solution for subcutaneous injection or intravenous infusion
Trial: NCT05201066
Drug: venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablet for oral administration
Trial: NCT05201066
Drug: INQOVI (oral decitabine)
RxNorm normalized name: Inqovi
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet for oral administration. HMA = azactidine or decitabine INQOVI = decitabine (oral)
Trial: NCT00522158
Drug: atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00269984
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05149326
Drug: KN046
RxNorm normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: KN046+Nab-Paclitaxel+Gemcitabine In combine therapy stage, KN046 is 5 milligram per kilogram, every 2 weeks. In maintain stage, KN046 is 5 milligram per kilogram, every 2 weeks.